Back to mobile site

Stifel on Oruka Therapeutics (ORKA): 'We expect shares to trade meaningfully-higher'

April 27, 2026 7:17 AM EDT Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $72.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst comments "16wk ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login